Change Visitor Type


Oxford BioTherapeutics

Oxford BioTherapeutics is an oncology drug discovery business. By exploiting its proprietary database of human cell-surface proteins, it creates and develops novel targeted oncology therapeutics, with a focus on Antibody Drug Conjugates and Immune Oncology treatments.

  • Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • Oxford BioTherapeutics strengthens board of Directors with appointment of two biotech veterans

    Read more
  • Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank

    Read more
  • $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics

    Read more
  • Oxford BioTherapeutics Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

    Read more